Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Immunogenicity of V118E in Healthy Adults
NCT07168915Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V118E in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Solicited Injection-Site Adverse Events at 7 days, Number of Participants With Solicited Systemic Adverse Events at 7 days and 5 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
V118E
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07168915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168915.